CYP2D6 inhibition by selective serotonin reuptake inhibitors: Analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6

Pharmacotherapy

Volumn 22, Issue 8, 2002, Pages 1001-1006

  Lam, Y W Francis ^a,b,c   Gaedigk, Andrea ^d   Ereshefsky, Larry ^a,b,c   Alfaro, Cara L ^e   Simpson, Joe ^f  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^d Children's Mercy Hospital   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^f Alamo Mental Health Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DEXTRORPHAN; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; PROSTAGLANDIN SYNTHASE INHIBITOR;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG URINE LEVEL; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIAL; BLOOD; DRUG ANTAGONISM; GENETICS; GENOTYPE; METABOLISM;

CYCLOOXYGENASE INHIBITORS; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; DEXTRORPHAN; FLUOXETINE; FLUVOXAMINE; GENOTYPE; HUMAN; PAROXETINE; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SUPPORT, NON-U.S. GOV'T; HUMANS;

EID: 0036021208     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.12.1001.33603     Document Type: Article

References (24)

1. Inhibition by paroxetine of desipramine metabolism in extensive but not poor metabolizers of sparteine
2. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects
3. Elevated serum phenytoin concentrations associated with coadministration of sertraline
4. CYP2D6 inhibition in patients treated with sertraline
5. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism
6. Pharmacokinetics of the newer antidepressants: Clinical relevance
7. CYP2D6 status of extensive metabolizers following multiple dose administration of fluvoxamine, fluoxetine, sertraline, or paroxetine
8. Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquine hydroxylation
9. High performance liquid chromatography determination of dextromethorphan and dextrorphan for oxidative phenotyping by fluorescence and ultraviolet detection
10. Pharmacokinetics of fluvoxamine maleate in patients with liver cirrhosis after single-dose oral administration
11. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data
12. Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping
13. Fluoxetine and norfluoxetine plasma concentrations in major depression: A multicenter study
14. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder
15. Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients
16. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences
17. The relationship between paroxetine and the sparteine oxidation polymorphism
18. Paroxetine steady-state plasma concentrations in relation to CYP2D6 genotype in extensive metabolizers
19. Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6
20. The effect of selective serotonin re-uptake inhibitors on cytochrome P450 2D6 (CYP2D6) activity in human liver microsomes
21. Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe
22. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction
23. Sertraline, like other SSRls, is a significant inhibitor of desipramine metabolism in vivo
24. Clinical implications of dose-dependent cytochrome P-450 drug-drug interactions with antidepressants